Abstract
tRNA is the adaptor in the translation process. The ribosome has three sites for tRNA, the A-, P-, and E-sites. The tRNAs bridge between the ribosomal subunits with the decoding site and the mRNA on the small or 30S subunit and the peptidyl transfer site on the large or 50S subunit. The possibility that translation release factors could mimic tRNA has been discussed for a long time, since their function is very similar to that of tRNA. They identify stop codons of the mRNA presented in the decoding site and hydrolyse the nascent peptide from the peptidyl tRNA in the peptidyl transfer site. The structures of eubacterial release factors are not yet known, and the first example of tRNA mimicry was discovered when elongation factor G (EF-G) was found to have a closely similar shape to a complex of elongation factor Tu (EF-Tu) with aminoacyl-tRNA. An even closer imitation of the tRNA shape is seen in ribosome recycling factor (RRF). The number of proteins mimicking tRNA is rapidly increasing. This primari ly concerns translation factors. It is now evident that in some sense they are either tRNA mimics, GTPases or possibly both.
Keywords: tRNA Binding, elongation factor g ef-g, elongation factor tu ef-tu, gtpases, eubacterial translation factors, initiation, elongation, termination, recycling, eucaryotic initiation factors 5a and b, ribosome release factor
Current Protein & Peptide Science
Title: Is tRNA Binding or tRNA Mimicry Mandatory for Translation Factors?
Volume: 3 Issue: 1
Author(s): Ole Kristensen, Martin Laurberg, Anders Liljas and Maria Selmer
Affiliation:
Keywords: tRNA Binding, elongation factor g ef-g, elongation factor tu ef-tu, gtpases, eubacterial translation factors, initiation, elongation, termination, recycling, eucaryotic initiation factors 5a and b, ribosome release factor
Abstract: tRNA is the adaptor in the translation process. The ribosome has three sites for tRNA, the A-, P-, and E-sites. The tRNAs bridge between the ribosomal subunits with the decoding site and the mRNA on the small or 30S subunit and the peptidyl transfer site on the large or 50S subunit. The possibility that translation release factors could mimic tRNA has been discussed for a long time, since their function is very similar to that of tRNA. They identify stop codons of the mRNA presented in the decoding site and hydrolyse the nascent peptide from the peptidyl tRNA in the peptidyl transfer site. The structures of eubacterial release factors are not yet known, and the first example of tRNA mimicry was discovered when elongation factor G (EF-G) was found to have a closely similar shape to a complex of elongation factor Tu (EF-Tu) with aminoacyl-tRNA. An even closer imitation of the tRNA shape is seen in ribosome recycling factor (RRF). The number of proteins mimicking tRNA is rapidly increasing. This primari ly concerns translation factors. It is now evident that in some sense they are either tRNA mimics, GTPases or possibly both.
Export Options
About this article
Cite this article as:
Kristensen Ole, Laurberg Martin, Liljas Anders and Selmer Maria, Is tRNA Binding or tRNA Mimicry Mandatory for Translation Factors?, Current Protein & Peptide Science 2002; 3 (1) . https://dx.doi.org/10.2174/1389203023380837
DOI https://dx.doi.org/10.2174/1389203023380837 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update
Current Topics in Medicinal Chemistry Novel Pthalazinyl Derivatives: Synthesis, Antimycobacterial Activities, and Inhibition of Mycobacterium Tuberculosis Isocitrate Lyase Enzyme
Medicinal Chemistry MicroRNA miR-122 as a Therapeutic Target for Oligonucleotides and Small Molecules
Current Medicinal Chemistry Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Oxidative Stress in HIV Patients Receiving Antiretroviral Therapy
Current HIV Research Synergistic Interplay of The Co-administration of Rifampin And Newly Developed Anti-TB Drug: Could It Be a Promising New Line of TB Therapy?
Combinatorial Chemistry & High Throughput Screening Non-Invasive Immunization on the Skin Using DNA Vaccine
Current Drug Delivery Cosignaling Complexity Gets More Convoluted: The Emerging Importance of the B7-Like Butyrophilin Family of Immune Regulators
Current Immunology Reviews (Discontinued) Bioorganic Approaches Towards HIV Vaccine Design
Current Pharmaceutical Design Prevention and Therapeutic Strategies of Thromboembolic Events in Patients with Inflammatory Bowel Diseases: A Report of Three Cases
Current Drug Targets Acetate Kinase (AcK) is Essential for Microbial Growth and Betel-derived Compounds Potentially Target AcK, PhoP and MDR Proteins in M. tuberculosis, V. cholerae and Pathogenic E. coli: An in silico and in vitro Study
Current Topics in Medicinal Chemistry Prevalence of HIV Drug Resistance Mutation in the Northern Indian Population After Failure of the First Line Antiretroviral Therapy
Current HIV Research Patients Characteristics and Clinical Implications of Suboptimal CD4 T-Cell Gains After 1 Year of Successful Antiretroviral Therapy
Current HIV Research Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets 4-Mer Hyaluronan Oligosaccharides Stimulate Inflammation Response in Synovial Fibroblasts in Part via TAK-1 and in Part via p38-MAPK
Current Medicinal Chemistry Streptococcal Collagen-like Protein 1 Binds Wound Fibronectin: Implications in Pathogen Targeting
Current Medicinal Chemistry A Remarkably Faster Approach Towards 1,2,3-Triazolyl Quinolines Via CuAAC in Water: Their Crystal Structure Analysis and Antibacterial Activities
Letters in Drug Design & Discovery Integrating Virtual Screening and Combinatorial Chemistry for Accelerated Drug Discovery
Combinatorial Chemistry & High Throughput Screening Type II NADH:Menaquinone Oxidoreductase of Mycobacterium tuberculosis
Infectious Disorders - Drug Targets Large Disclosing the Nature of Computational Tools for the Analysis of Next Generation Sequencing Data
Current Topics in Medicinal Chemistry